Molina Healthcare, Inc. (MOH) Stock Price & Analysis
Molina Healthcare, Inc. (MOH) closed at USD 216.64 on Thursday, October 22, 2026, up 0.81% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 214.9; the Oct 22, 2026 session ranged USD 206.7–225.88 on volume of 1,815,391 shares. Market capitalization is $11.31B, with a 52-week range of USD 121.06–244.89 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MOH.md
Key facts (MOH)
- Last four reported quarters (through Sep 30, 2026): revenue $44.1B, net income -$48.0M (-0.1% margin), free cash flow $238M (SEC filings).
- 3 of 80 tracked superinvestors hold MOH (13F, Q2 2026 (1 investor on Q3 2025, filed early)): 1 new, 0 added, 1 reduced, 1 unchanged.
- Analysts: Hold (mean 2.95 on a 1–5 scale) (19 analysts), mean target USD 214.94 (range 147–266).
- Total return with dividends: 1Y +34.6% vs S&P 500 +14.9%; 5Y -27.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 0.51, revenue estimate $11.7B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MOH)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $27.8B | $32.0B | $34.1B | $40.6B | $45.4B | $44.1B |
| Gross profit | $4.07B | $4.80B | $5.40B | $6.22B | $5.94B | — |
| Operating income | $1.02B | $1.17B | $1.57B | $1.71B | $781M | $172M |
| Net income | $659M | $792M | $1.09B | $1.18B | $472M | -$48.0M |
| EPS (diluted) | $11.25 | $13.55 | $18.77 | $20.42 | $8.92 | — |
| Free cash flow | $2.04B | $682M | $1.58B | $544M | -$636M | $238M |
| Gross margin | 14.6% | 15.0% | 15.9% | 15.3% | 13.1% | — |
| Operating margin | 3.7% | 3.7% | 4.6% | 4.2% | 1.7% | 0.4% |
| Net margin | 2.4% | 2.5% | 3.2% | 2.9% | 1.0% | -0.1% |
| Revenue growth | +43.0% | +15.1% | +6.6% | +19.3% | +11.7% | — |
| Cash + short-term investments | $7.64B | $7.50B | $9.11B | $8.99B | $8.26B | — |
| Total debt | $2.17B | $2.18B | $2.18B | $2.92B | $3.77B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (MOH)
P/S 0.3x · EV/EBITDA 19.5x · EV/Sales 0.1x · P/FCF 47.5x · P/B 2.7x · FCF yield 2.10% · Earnings yield -0.42% · Buyback yield (TTM) 0.00% · Net cash $4.81B · EV $6.50B
P/E at fiscal year-ends: Dec 2025 19.4x, Dec 2024 14.2x, Dec 2023 19.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (MOH)
3 of 80 tracked investors hold MOH (1 investor on Q3 2025, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Michael Burry | Scion Asset Management | 35.11% | $23.9M | New position | Q3 2025 |
| Seth Klarman | Baupost Group | 2.68% | $145M | Unchanged | Q2 2026 |
| Bill Nygren | Oakmark Funds | 0.29% | $219M | Reduced -2.1% | Q2 2026 |
Analysts (MOH)
Consensus Hold (mean 2.95 on a 1–5 scale), 19 analysts; mean target USD 214.94 (low 147, high 266).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | Wells Fargo | Target lowered | Equal-Weight | $235 → $220 |
| 2026-07-24 | Truist Securities | Target lowered | Hold | $250 → $225 |
| 2026-07-24 | RBC Capital | Target lowered | Sector Perform | $248 → $218 |
| 2026-07-24 | Barclays | Target lowered | Underweight | $184 → $180 |
| 2026-07-14 | TD Cowen | Target raised | Hold | $163 → $230 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $205 → $250 |
| 2026-07-13 | Wells Fargo | Target raised | Equal-Weight | $159 → $235 |
| 2026-07-09 | RBC Capital | Target raised | Sector Perform | $216 → $248 |
| 2026-07-09 | Barclays | Target lowered | Underweight | $199 → $184 |
Total return (dividends reinvested) (MOH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +34.6% | -27.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +34.7% | -6.2% |
| Volatility (annualized) | 52.4% | 39.5% |
| Max drawdown | -39.3% (Jan 2026→Feb 2026) | -68.2% (Mar 2024→Feb 2026) |
Companies that name MOH in their SEC reports
| Relationship to MOH | Company | Filing | Sentence |
|---|---|---|---|
| partner | Evolent Health, Inc. (EVH) | 10-K Feb 25, 2026 | “Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue for the year ended December 31, 2025.” |
MOH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $0.51 | $0.54 | -5.9% | $11.70B | 7 |
| Next quarter (ends Mar 2027) | $3.06 | $3.05 | +0.3% | $11.71B | 13 |
| Current fiscal year (ends Dec 2026) | $5.25 | $5.22 | +0.7% | $44.54B | 19 |
| Next fiscal year (ends Dec 2027) | $9.58 | $8.55 | +12.0% | $47.40B | 5 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 216.64 |
|---|---|
| Change | ▲ 0.81% (up) |
| Previous Close | USD 214.9 |
| Open | USD 211.68 |
| Day Range | USD 206.7 – 225.88 |
| 52-Week Range | USD 121.06 – 244.89 |
| Volume | 1,815,391 shares |
| Market Cap | $11.31B |
| Exchange | NYQ |
Technical Analysis (MOH)
Nexqual's technical model rates MOH "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.38 (neutral) |
| vs SMA50 | Above (USD 200.74) |
| MACD | 4.88 (positive) |
Analyst Ratings (MOH)
Wall Street analysts rate MOH "Hold" based on 19 analysts, with a mean price target of USD 214.94 (range USD 147–266), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 214.94 |
| High Target | USD 266 |
| Low Target | USD 147 |
| Buy / Hold / Sell | 3 / 15 / 1 |
Earnings (MOH)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 0.51 |
| Revenue Estimate | $11.70B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 0.89 vs est 0.79 ▲ beat |
| 2026-06-30 | USD 1.51 vs est 1.4 ▲ beat |
| 2026-03-31 | USD 2.35 vs est 1.91 ▲ beat |
| 2025-12-31 | USD -2.75 vs est 0.33 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (MOH)
| Total Revenue | $42.08B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -3.50% |
| Gross Margin | +8.35% |
| Operating Margin | +1.00% |
| Profit Margin | -0.11% |
| ROE | -1.15% |
| Debt / Equity | 0.95 |
| Current Ratio | 1.69 |
| Total Cash | $8.58B |
| Total Debt | $3.95B |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | $238.00M (0.5% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (MOH)
Nexqual rates Molina Healthcare, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 8%, operating 1% (last 12 months) |
| Balance Sheet | Mixed — $8.58B cash and investments vs $3.77B debt (Sep 2026, SEC), net cash |
| Cash Flow | Mixed — FCF $238M (last 4 quarters to Sep 2026, SEC), slim 0.5% margin |
| Efficiency | Critical — ROE -1%, ROA 1.1% |
Ownership (MOH)
| Insider Ownership | +1.42% |
|---|---|
| Institutional Ownership | +111.91% |
| Shares Outstanding | 52.20M |
| Float | 47.70M |
| Short % of Float | +6.46% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (MOH)
Molina Healthcare, Inc. is led by Joseph Michael Zubretsky, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:26 UTC.
| President, CEO & Director | Joseph Michael Zubretsky |
|---|---|
| Senior EVP, CFO & Treasurer | Mark Lowell Keim |
| Senior EVP & COO | James Edwin Woys |
| Executive Vice President of Medicaid | Debra Jean Bacon |
| Vice President of Compliance | Joann Zarza-Garrido |
Major Backers & Investors (MOH)
Notable institutional backers of Molina Healthcare, Inc. include AQR Capital Management, LLC, Capital Group, Lingotto Investment Management LLP, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Capital Management, LLC | 6.82% |
| Capital Group | 4.91% |
| Lingotto Investment Management LLP | 4.81% |
| Victory Capital Management Inc. | 3.79% |
| FMR, LLC | 3.58% |
| Victory Portfolios-Victory Sycamore Established Value Fund | 2.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.59% |
| Vanguard Group | 9.86% |
| State Street | 3.36% |
| Dimensional Fund Advisors | 2.67% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OSCR | Oscar Health, Inc. | USD 33.32 | ▼ 0.39% |
| CNC | Centene Corporation | USD 71.24 | ▲ 1.42% |
| CLOV | Clover Health Investments, Corp | USD 4.73 | ▼ 1.05% |
| HUM | Humana Inc. | USD 420.97 | ▼ 1.05% |
| PGNY | Progyny, Inc. | USD 29.12 | ▲ 2.39% |
| ALHC | Alignment Healthcare, Inc. | USD 8.43 | ▼ 0.12% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt